The U.S. Food and Drug Administration is experiencing significant leadership upheaval, highlighted by the announced retirement of Jacqueline Corrigan-Curay, acting head of the Center for Drug Evaluation and Research (CDER), effective July 2025. Corrigan-Curay's departure follows recent administrative leaves of key officials like Nicole Verdun and Rachael Anatol amid internal disagreements. This period of rapid turnover raises questions about the agency's continuity and regulatory approach, coinciding with Commissioner Marty Makary’s leadership and initiatives to reshape drug approvals and regulatory standards.